About 6,420,000 results
Open links in new tab
AZ, Daiichi's Enhertu cleared by FDA in wide range of tumors
Enhertu demonstrated a median progression-free survival of 13.2 …
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the …
Enhertu demonstrated clinically meaningful survival across …
ENHERTU ® Granted Two Breakthrough Therapy ... - Business Wire
Enhertu demonstrated statistically significant and clinically ...
Enhertu Dramatically More Effective Than Kadcyla as Second …
ENHERTU® Showed Substantial Clinical Activity in Patients with …
Enhertu Effective in HER2-Positive Metastatic Breast Cancer